Pharmafile Logo
Pharmafocus logo
Advanced Search

juno therapeutics

Showing 12 posts of 12 posts found.

hans-bishop_2x

Juno CEO and Co-founder steps down in wake of Celgene acquisition

April 25, 2018
Medical Communications, Research and Development Celgene, appointment, juno therapeutics, pharma

Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown …

News
pharmafocus_janfeb__cover

Read Pharmafocus January/February 2018 edition online now!

January 30, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Ablynx, Alex Azr, Celgene, Pharmafocus, Sanofi, UK, artificial intelligence, bioverativ, brexit, juno therapeutics, multiple myeloma, serialisation

With the holiday period a distant memory by now, Pharmafocus is back with its January/febraury edition. It’s hard to imagine …

News
celgene_exteriors-3

Celgene confirms rumours, with $9bn deal for Juno

January 22, 2018
Manufacturing and Production, Sales and Marketing CAR-T, Celgene, biotech, drugs, juno therapeutics, pharma, pharmaceutical

It seems like 2018 may well be the year for M&A that everyone had expected, as two major deals on …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten

It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …

News
cindy_elkins_2x

Ex-Genentech exec named as new Juno Therapeutics CIO

January 8, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, juno therapeutics

Biopharmaceutical firm and cellular immunotherapy specialist Juno Therapeutics has named Cindy Elkins as its new Chief Information Officer, where she …

Appointment

Juno Therapeutics bring in new executive vice president

January 27, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genentech, Roche, juno therapeutics

Juno Therapeutics has hired Corsee D. Sanders as its executive vice president and head of development operations. She will step …

Appointment
juno

Patient deaths lead Juno Therapeutics to halt trial for second time

November 24, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acute lymphoblastic leukaemia, clinical trial deaths, juno therapeutics

Juno Therapeutics has been forced to halt a trial investigating the efficacy of its lead experimental CAR-T cancer treatment JCAR015 …

News
stocks1

Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…

July 15, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics

Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …

Feature

Busy week at Juno Therapeutics ends with takeover of RedoxTherapies

July 15, 2016
Medical Communications, Research and Development, Sales and Marketing juno therapeutics, redoxtherapies, takeover, vipadenant

Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.

News
junologo

US FDA lifts hold on Juno’s CAR-T therapy trials; shares jump

July 13, 2016
Research and Development, Sales and Marketing Stock Price, US FDA, drug trial, juno therapeutics

Shares in Juno Therapeutics (Nasdaq: JUNO) jumped to close up almost 30% after the company said the US Food and …

News
stocks1

Weekly Movers: Medivation, Bind Therapeutics, Insys…

July 11, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Medivation, XBiotech, juno therapeutics, markets, stocks

Medivation (Nasdaq: MDVN) stock rose after the company announced it has entered a confidentiality agreement with a number of parties …

Feature
chemo-web

FDA suspends Juno Therapeutics cancer drug trial after patient deaths

July 8, 2016
Medical Communications, Research and Development FDA, juno therapeutics, patient deaths

Juno Therapeutics (NASDAQ: JUNO) has had its Phase II trial investigating JCAR015 in adult patients with relapsed or refractory B …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024